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Squamous cell carcinomas of the anus and anal canal represent a model of a cancer and perhaps the first where level 1 evidence
supported primary chemoradiotherapy (CRT) in treating locoregional disease with curative intent. The majority of tumours are
associated with infection with oncogenic subtypes of human papilloma virus and this plays a significant role in their sensitivity to
treatment. However, not all tumours are cured with CRT and there remain opportunities to improve outcomes in terms of
oncological control and also reducing late toxicities. Understanding the biology of ASCC promises to allow a more personalised
approach to treatment, with the development and validation of a range of biomarkers and associated techniques that are the
focus of this review.
Anal squamous cell carcinomas (ASCC) are increasing in
frequency across the developed world (Johnson et al, 2004;
Wilkinson et al, 2014; Bouvier et al, 2016). Associated with
oncogenic subtypes of the human papilloma viruses (HPV;
Baricevic et al, 2015) they typically present at a localised stage
with or without regional lymph node involvement. Aside from in
the earliest tumours, where the majority may be excised surgically,
the international standard of care is chemoradiotherapy (CRT). As
first appreciated by Nigro et al, ASCC demonstrate marked
sensitivity to this combined modality of treatment, which
additionally avoids the need for radical surgery and permanent
colostomy (Nigro et al, 1983). Although 6 phase III clinical trials
have been reported in ASCC investigating alternative chemothera-
pies, there is no benefit from adjuvant or maintenance chemother-
apy and concurrent chemoradiotherapy with Mitomycin, and 5FU
remains the standard of care with 65–74% 3-year local control
(Spithoff et al, 2014). However, all have posed clinical questions
without any correlative biology or stratification beyond clinical and
stage-related prognostic markers.
It is increasingly appreciated that the biology of HPV transforma-
tion contributes to the chemo/radio sensitivity seen in ASCC, a
characteristic most extensively investigated in head and neck cancer
(Swick et al, 2015). An improved understanding of the underlying
factors involved in this process, and those that mediate resistance and
relapse would offer significant opportunities in improving outcomes
across the spectrum of ASCC. Furthermore, as we will detail, ASCC as
a model system might provide further insights into cancer biology
across the spectrum of HPV-associated malignancies.
TRANSLATIONAL QUESTIONS IN ANAL CANCER
While the relative sensitivity of ASCC to CRT means that
oncologic outcomes appear reasonable, key translational questions
remain and for certain groups of patients, outcomes remain poor.
Although data around late toxicity from anal cancer CRT is limited
(Bentzen et al, 2013) up to 30% patients experience debilitating
side effects, particularly in terms of bowel function. Surgery is
currently reserved for relapsing cases, where there is a clear benefit
to operating early (Renehan et al, 2005) and as such prompt
detection of residual/recurrent disease, or even identification of
tumours that are primarily resistant to CRT would have significant
clinical benefit.
In terms of utilising biomarkers to improve outcomes, first,
factors that are predictive of response would facilitate modulation
of components of CRT (i.e., radiotherapy dose or novel combina-
tion therapeutics) either aiming to improve response rates in poor
risk disease, or potentially de-intensify treatment to avoid excessive
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late toxicity (as currently being tested in the setting of head and
neck cancers (Owadally et al, 2015)). There is considerable
variation in radiotherapy doses used, from the relatively lower
doses in the initial series (Nigro et al, 1983), through 50.4Gy in
ACT2 to 54–64Gy in the Nordic countries (Leon et al, 2014).
Second techniques that aided the early detection of relapse would
facilitate prompt salvage surgery with improved outcomes.
In addition, there is the potential to investigate whether
underlying genomic factors modulate HPV-induced transforma-
tion of cells (Levovitz et al, 2014) and subsequent clinical
behaviour or mediate toxicity from radiotherapy as described in
prostate cancer (Fachal et al, 2014). An understanding of the
mechanisms that mediate relapse, dissemination and resistance will
identify technology and targets for future therapy in a disease
where currently there is only palliative cytotoxic chemotherapy
with limited response rates and poor outcomes.
Importantly, given the ultimate aim of developing any
biomarker is to improve clinical outcomes, it is vital that tests
are sufficiently robust and reproducible in terms of assay
development, and then prospectively validated, ideally in the
context of a randomised controlled trial, as detailed in Cancer Research
UK’s biomarker roadmap; (http://www.cancerresearchuk.org/sites/
default/files/prognostic_and_predictive.pdf).
CURRENT BIOMARKERS OF RESPONSE TO
CHEMORADIOTHERAPY
A number of variables are reported to contribute to the
heterogeneity in outcomes seen in patients with ASCC (Das
et al, 2008). These include measurement of the extent of a patient’s
disease as conferred by the tumour size and nodal status, each of
which independently predicts disease-free and overall survival
(OS). It has also been reported that initial response to treatment
with radiotherapy correlates with the extent of both local control
and OS. However, despite their overall prognostic value,
clinicopathologic factors do not consistently enable prediction of
response to currently available treatment modalities. There there-
fore remains a requirement for predictive markers to guide
clinicians’ choice of treatment.
In a previous systematic review of 21 studies published before
2010, Lampejo et al identified 13 biomarkers associated with
outcome in ASCC (Lampejo et al, 2010). Of these, only p53 and
p21 were shown to have prognostic utility in more than one study,
yet their value was not universally supported by the reported
literature. Other reported prognostic biomarkers – testable markers
postulated to provide information relating to a patient’s outcome –
included numerous tumour suppressor genes, apoptotic regulators,
tumour markers and factors involved in angiogenesis, proliferation
and invasion.
A number of subsequent retrospective analyses have highlighted
the potential prognostic utility of identifying tumour HPV
involvement, either directly or through analysis of its surrogate
marker, p16 overexpression. A systematic search of PubMed
(August 2006–August 2016) using the terms: p16 AND/OR HPV/
human papilloma virus AND outcome OR prognosis/prognostic
AND anal squamous cell carcinoma OR anal carcinoma was
performed. Only those relating to the specific prognostic utility of
HPV/p16 in anal squamous cell carcinoma patients managed with
chemoradiotherapy were selected. References of those papers
selected to be of potential relevance based on their abstract were
also reviewed.
As shown in Table 1, OS, recurrence and both locoregional and
systemic failure are reported to correlate with high p16 expression
and the presence of HPV DNA. Given that the prevalence of HPV
DNA is universally reported to be high, additional prognostic
subsets have been generated through the detection of the specific
HPV genotype HPV16, either alone or in combination with p16.
The most widely studied outcome with respect to HPV/p16
status is OS. In univariate analyses, significant associations have
been reported between 3- to 10-year survival and both p16
expression and the detection of HPV and HPV16 DNA. There
nevertheless remain inconsistencies and in the studies included
here, p16 status significantly correlated with OS in only half of the
patient populations in which it was analysed. Though reported in
fewer manuscripts, both recurrence and locoregional failure have
also been consistently significantly associated with HPV, HPV16
and p16 status. This is in contrast to systemic failure, which to our
knowledge significantly correlates with HPV/p16 status in only two
reports to date.
In multivariate analyses, HPV16 and p16 are both reported to
be independently predictive of PFS and OS (Yhim et al, 2011;
Gilbert et al, 2013; Ravenda et al, 2014; Serup-Hansen et al, 2014;
Baricevic et al, 2015; Mai et al, 2015; Rodel et al, 2015). Mai et al
additionally report an independent association between combined
HPV/p16 status and PFS (Mai et al, 2015). In contrast, Koerber
and Meulendijks identified no independent associations for HPV
or p16 alone, but reported combined HPV and p16 to be predictive
of both PFS and OS (Koerber et al, 2014; Meulendijks et al, 2015).
The studies outlined here are retrospective and small. Median
follow-up ranges between 27.9–59.0 months, over which time the
outcomes of between 47 and 110 patients were studied. This may
contribute to the inconsistencies in the outcomes reported here.
However, given that the majority of tumours are HPV positive
(noting that not all HPV DNA-positive ASCC, and particularly
those solely p16-positive, can be causally related to HPV (Prigge
et al, 2016) where the gold standard to indicate a transcriptionally
active (transforming) HPV infection is detection of E6/E7 mRNA
(von Knebel Doeberitz, 2016)) additional biomarkers over and
above HPV status are required to guide treatment stratification.
MOLECULAR MECHANISMS FOR DIFFERENTIAL
SENSITIVITY TO CRT IN HPV± CASES
Improved technologies (predominately next generation sequen-
cing) have begun to offer explanations for the differential
sensitivities seen between HPVþ and  ve tumours, accepting
the subtleties of this distinction as detailed above. As previously
discussed, increased protein expression of p53 (associated with
mutations that cause the protein to remain detectable) has
previously been associated with worse outcomes after CRT and is
inversely correlated with p16/HPV (Gilbert et al, 2013). Sequen-
cing data confirms that p53 mutations and HPV involvement are
for the most part mutually exclusive in ASCC (Meulendijks et al,
2015) being found in HPV ve cases in a manner parallel to that
seen in head and neck cancer (Westra et al, 2008). Inactivation of
p53 seems to be an essential step in tumourigenesis. In HPVþ ve
tumours this arises through the action of HPV E6, though
potentially this can be overcome if sufficient DNA damage
(i.e.,CRT) occurs. In the absence of E6 (i.e., HPV ve cases), such
suppression of activity must arise through mutation, meaning p53
activity is unrecoverable and DNA damage goes undetected
(Figure 1).
A number of studies have used broader genomic profiling to
investigate cohorts of ASCC, using a mixture of pre-treatment
biopsies and samples from relapsing patients. A combination of
immunohistochemistry, in situ hybridisation and targeted sequen-
cing was applied to 199 ASCC (Smaglo et al, 2015). A total of 89%
cases expressed EGFR, though amplification was infrequent (7.4%)
and no mutations were recorded. The most commonly mutated
gene was PIK3CA (33% samples) with TP53 second most frequent
in 15%. Further evidence of the high frequency of these mutations
BRITISH JOURNAL OF CANCER Biomarkers in anal cancer
2 www.bjcancer.com |DOI:10.1038/bjc.2016.398
Ta
b
le
1.
A
su
m
m
ar
y
o
f
re
p
o
rt
ed
as
so
ci
at
io
ns
b
et
w
ee
n
p
16
(im
m
un
o
hi
st
o
ch
em
is
tr
y)
an
d
H
P
V
st
at
us
(u
si
ng
P
C
R
),
an
d
o
ut
co
m
e
fr
o
m
an
al
sq
ua
m
o
us
ce
ll
ca
rc
in
o
m
a
tr
ea
te
d
w
it
h
ch
em
o
ra
d
io
th
er
ap
y
C
o
rr
el
at
io
n
w
it
h
o
ut
co
m
ec
P
at
ie
nt
s;
n
(%
M
:F
)a
M
ed
ia
n
fo
llo
w
-u
p
(m
o
nt
hs
)
M
ar
ke
r
%
H
ig
h
ri
sk
b
Su
rv
iv
al
R
ec
ur
re
nc
e
Lo
co
re
g
io
na
lf
ai
lu
re
Sy
st
em
ic
fa
ilu
re
Yh
im
et
al
(2
01
1)
47
(4
7
:5
3)
51
.7
H
PV
16
66
.0
(3
1/
47
)
4
ye
ar
O
S
ra
te
:
P
¼
0.
00
8.
84
.6
%
vs
39
.8
%
4-
ye
ar
PF
S
ra
te
:
Po
0.
00
1.
63
.1
%
vs
15
.6
%
4-
ye
ar
TT
LF
ra
te
:
P
¼
0.
00
6.
76
.3
%
vs
36
.8
%
4-
ye
ar
TT
SF
ra
te
:
N
S
p
16
83
.0
(3
9/
47
)
N
S
4-
ye
ar
PF
S:
P
¼
0.
01
4.
52
.5
%
vs
25
.0
%
4-
ye
ar
TT
LF
:
P
¼
0.
01
8.
69
.3
%
vs
42
.9
%
4-
ye
ar
TT
SF
ra
te
:
N
S
d
G
ilb
er
t
et
al
(2
01
3)
15
3
(3
9
:6
1)
27
.9
p
16
89
.5
(1
37
/1
53
)
N
/A
Re
la
p
se
ra
te
:P
¼
0.
00
76
.
27
.0
%
vs
62
.5
%
N
/A
N
/A
Ra
ve
nd
a
et
al
(2
01
4)
50
(2
6
:7
4)
48
.0
H
PV
84
.0
(4
2/
50
)
5
ye
ar
O
S:
N
S
5-
ye
ar
PF
S:
P
o
0.
01
.
92
.5
vs
50
.0
%
N
/A
N
/A
K
oe
rb
er
et
al
(2
01
4)
90
(1
4
:8
6)
48
.6
H
PV
83
.3
(7
5/
90
)
O
S
ra
te
:
P
¼
0.
00
7.
75
.8
%
vs
48
.0
%
PF
S:
P
o
0.
00
1.
63
.5
%
vs
26
.7
%
3-
ye
ar
lo
ca
lc
on
tr
ol
ra
te
:
N
S
Ri
sk
of
d
is
ta
nt
re
cu
rr
en
ce
:
P
¼
0.
00
5
p
16
83
.3
(7
5/
90
)
O
S
ra
te
:
N
S
PF
S:
Po
0.
00
17
.
62
.3
%
vs
33
.3
%
N
/A
N
/A
H
PV
p
16
77
.8
(7
0/
90
)
O
S
ra
te
:
P
¼
0.
00
5.
77
.1
%
vs
51
.4
%
PF
S:
P
o
0.
00
1.
64
.0
%
vs
35
.0
%
3-
ye
ar
lo
ca
lc
on
tr
ol
ra
te
:
P
¼
0.
02
3;
81
.0
%
vs
55
.9
%
N
/A
e
Ro
ld
a´n
U
rg
oi
ti
et
al
(2
01
4)
53
(2
5
:7
5)
59
.0
p
16
80
(2
8/
35
)
5-
ye
ar
O
S:
P
¼
0.
01
.
H
R
4.
5
(9
5%
C
I1
.4
–1
5)
5-
ye
ar
PF
S:
P
¼
0.
00
6.
H
R
8.
4
[9
5%
C
I
1.
8–
38
.6
]
V
er
y
hi
g
h
A
Q
U
A
sc
or
e
(4
24
4)
as
so
ci
at
ed
w
ith
hi
g
he
r
in
ci
d
en
ce
of
lo
ca
lo
r
d
is
ta
nt
re
cu
rr
en
ce
(P
¼
0.
00
4)
Se
ru
p
-H
an
se
n
et
al
(2
01
4)
14
3
(2
6
:7
4)
51
.2
H
PV
87
.6
(1
20
/1
37
)
5-
ye
ar
O
S:
P
¼
0.
03
6.
74
%
vs
52
%
N
/A
N
/A
N
/A
p
16
92
.9
(1
31
/1
41
)
5-
ye
ar
O
S:
P
o
0.
00
1.
76
%
vs
30
%
N
/A
N
/A
N
/A
Ro
d
el
et
al
(2
01
5)
95
(4
3
:5
7)
40
.0
H
PV
16
95
.8
(9
1/
95
)
10
-y
ea
r
O
S:
P
¼
0.
02
0.
H
R
2.
86
(9
5%
C
I1
.1
–7
.1
)
N
/A
Lo
ca
lf
ai
lu
re
ra
te
:
P
¼
0.
02
3.
N
S
p
16
65
.2
(6
2/
95
)
N
S
N
/A
Lo
ca
lf
ai
lu
re
ra
te
:
P
¼
0.
02
1.
N
S
H
PV
16
p
16
U
10
-y
ea
r
O
S:
P
¼
0.
03
1.
N
/A
Lo
ca
lf
ai
lu
re
ra
te
:
P
¼
0.
01
9.
N
/A
M
eu
le
nd
ijk
s
et
al
(2
01
5)
10
7
(4
7
:5
3)
30
.0
H
PV
87
.0
(9
3/
10
7)
3-
ye
ar
O
S:
P
o
0.
00
1.
87
%
vs
35
%
N
/A
3-
ye
ar
TT
LF
ra
te
:
P
o
0.
00
1.
82
%
vs
15
%
N
S
p
16
91
.0
(9
7/
10
7)
N
S
N
/A
3-
ye
ar
TT
LF
ra
te
:
Po
0.
07
8.
75
%
vs
15
%
N
S
d
B
ar
ic
ev
ic
et
al
(2
01
5)
11
0
(4
3
:5
7)
28
.0
H
PV
16
85
.0
(9
3/
11
0)
5-
ye
ar
O
S:
P
¼
0.
01
9.
59
%
vs
38
%
5-
ye
ar
RF
S:
P
¼
0.
02
7.
62
%
vs
40
%
N
/A
N
/A
p
16
89
.0
(9
8/
11
0)
5-
ye
ar
O
S:
P
o
0.
00
1.
63
%
vs
13
%
5-
ye
ar
RF
S:
Po
0.
00
1.
65
%
vs
16
%
N
/A
N
/A
M
ai
et
al
(2
01
5)
10
6
(4
1
:5
9)
48
.0
(L
C
)5
4.
0
(O
S)
H
PV
p
16
59
.0
(6
3/
10
6)
5-
ye
ar
O
S:
P
¼
0.
01
1.
81
.1
%
vs
68
.8
%
N
/A
5-
ye
ar
LC
:
P
¼
0.
00
2.
88
.1
%
vs
55
.8
%
N
/A
A
b
b
re
vi
at
io
ns
:H
R,
ha
za
rd
ra
tio
;H
PV
,h
um
an
p
ap
ill
o
m
a
vi
ru
se
s;
N
A
,n
o
ta
va
ila
b
le
/r
ep
o
rt
ed
;N
S,
no
ts
ig
ni
fic
an
t;
O
S,
o
ve
ra
ll
su
rv
iv
al
;P
FS
,p
ro
g
re
ss
io
n
fr
ee
su
rv
iv
al
;T
TL
F,
tim
e
to
lo
co
re
g
io
na
lf
ai
lu
re
;T
TS
F,
tim
e
to
sy
st
em
ic
fa
ilu
re
O
ut
co
m
es
fr
o
m
un
iv
ar
ia
te
an
al
ys
es
ar
e
sh
o
w
n.
K
ey
:O
S
–
tim
e
fr
o
m
th
e
d
at
e
o
fd
ia
g
no
si
s
to
th
e
d
at
e
o
fd
ea
th
fr
o
m
an
y
ca
us
e;
PF
S
–
tim
e
fr
o
m
th
e
d
at
e
o
fd
ia
g
no
si
s/
fir
st
d
ay
o
ft
re
at
m
en
tt
o
th
e
fir
st
d
o
cu
m
en
te
d
d
at
e
o
fp
ro
g
re
ss
io
n;
TT
LF
–
tim
e
fr
o
m
th
e
fir
st
d
ay
o
ft
re
at
m
en
tt
o
th
e
fir
st
d
o
cu
m
en
te
d
d
at
e
o
f
d
is
ea
se
p
ro
g
re
ss
io
n;
TT
SF
–
tim
e
fr
o
m
th
e
fir
st
d
ay
o
f
tr
ea
tm
en
t
to
th
e
fir
st
d
o
cu
m
en
te
d
d
is
ta
nt
m
et
as
ta
si
s.
H
R,
p
ro
vi
d
ed
he
re
w
he
n
un
iv
ar
ia
te
co
m
p
ar
is
o
ns
no
t
av
ai
la
b
le
fr
o
m
te
xt
.
a
St
at
is
tic
al
ly
si
g
ni
fic
an
t
co
m
p
ar
is
o
ns
sh
o
w
n.
A
ll
p
o
si
tiv
e
vs
ne
g
at
iv
e
un
le
ss
o
th
er
w
is
e
st
at
ed
.
b
Su
b
je
ct
s
fo
r
w
ho
m
b
io
m
ar
ke
r
p
o
si
tiv
ity
co
ul
d
b
e
as
se
ss
ed
.
c ‘
H
ig
h
ris
k’
d
ee
m
ed
as
hi
g
h
p
16
ex
p
re
ss
io
n
an
d
ei
th
er
th
e
d
et
ec
tio
n,
o
r
hi
g
h
le
ve
ls
o
f,
H
PV
D
N
A
.
d
O
ve
rla
p
p
in
g
co
ho
rt
o
f
p
at
ie
nt
s.
e
D
at
a
re
la
te
to
p
at
ie
nt
s
w
ith
a
p
re
-t
re
at
m
en
t
ha
em
o
g
lo
b
in
o
f
12
0
g
l
1 .
Lo
w
er
p
re
-t
re
at
m
en
t
ha
em
o
g
lo
b
in
w
as
id
en
tif
ie
d
as
an
in
d
ep
en
d
en
t
p
ro
g
no
st
ic
fa
ct
o
r
fo
r
p
o
o
re
r
O
S
an
d
PF
S.
Biomarkers in anal cancer BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.398 3
comes from data (using a 236 gene NGS panel) from 70 anal
cancers (Chung et al, 2016). In total, 87% were HPV positive. The
most frequent mutations again involved PIK3CA (40% cases), with
PTEN loss seen in an additional 14%. TP53 and CDKN2a
mutations were seen predominately in HPV negative cases where
6/9 tumours had mutations in TP53 mutation, and 5/9 CDKN2A.
Five cases (all HPVþ ve) had amplification at 11q13 (a region that
includes FGF3, FGF4, FGF19 and CCND1). No associations
between these molecular abnormalities and tumour stage or
clinical behaviour were reported.
A recent study (Cacheux et al, 2016) provides further evidence
for these relationships, sequencing 8 genes (KRAS, NRAS, HRAS,
BRAF, PIK3CA, MET, TP53 and FBXW7) in 148 ASCC patients
including 52 recurrences post CRT. A total of 30 patients (20.3%)
demonstrated PIK3CA mutations and 7 patients (4.7%) demon-
strated mutations in TP53, the latter only seen in recurrent
tumours and associated with HPV ve tumours (3/131 HPVþ ve
vs 4/17 HPV ve). Three had mutations in KRAS whereas NRAS,
HRAS and BRAF were wild-type throughout.
The importance of PI3 kinase signalling in ASCC, predomi-
nately through a high frequency of activating PIK3CA mutations,
is a feature of other HPV-associated squamous cell carcinomas. In
total, 30% cervical cancers harbour PIK3CA mutations associated
with poor outcomes following chemoradiotherapy (McIntyre et al,
2013; de la Rochefordiere et al, 2015), but similar findings are also
reported in vulval (Trietsch et al, 2014) and penile cancers
(McDaniel et al, 2015). Similarly the inverse relationship between
HPV involvement and TP53 mutations is documented in HNSCC
(Westra et al, 2008) and vulval cancer (Trietsch et al, 2014).
HOST IMMUNE RESPONSE AND OUTCOME FROM CRT
The mutational profiling demonstrates differing routes to trans-
formation (HPV±) that appear to impact on clinical outcomes.
However, the host response to ASCC is also a powerful arbiter of
the effectiveness of CRT. One phenotypic readout of the local
immune response can be seen in the extent of infiltration of
lymphocytes into the tumour. Measurement of tumour infiltrating
lymphocytes (TIL) adds prognostic value to HPV status in head
and neck cancer (Ward et al, 2014), where patients with HPVþ ve
tumours but low levels of TILs had similar outcomes (PFS and OS)
as HPV ve cases. In HPVþ ve HNSCC cases TIL status
outperformed smoking and T-stage as prognostic variables.
Importantly, from a mechanistic perspective, these cohorts
included patients with HNSCC treated with surgery, suggesting a
prognostic effect of both HPV status and TIL across treatment
modalities (and hence not simply related to sensitivity to CRT
through TP53 mutations as discussed earlier).
Parallel findings have been demonstrated in ASCC (Gilbert et al,
2016). Using cohorts of ASCC from the UK and Denmark treated
with CRT with published clinical outcomes and known HPV status
(Gilbert et al, 2013; Serup-Hansen et al, 2014), high levels of TIL
showed improved outcomes in the HPVþ ve patients, whereas
patients with low levels of TIL had outcomes more in keeping with
HPV ve tumours. This finding requires validation in a cohort of
samples large enough for robust multivariate analysis to include all
clinical and radiological factors but raises the possibility that
modulating the host response to the tumour could improve
therapeutic response.
Lymphocyte infiltrates represent a visual readout of the local
host response, but a more detailed understanding (e.g., relative
CD4/CD8 and antibody responses) of the nature of this response
should facilitate improved prognostic ability and important
opportunities for therapeutic intervention.
PLASMA-BASED MONITORING OF DISEASE
Anal Cancer presents a compelling case for developing serial, non-
invasive markers of response/relapse, given that the tumour is
treated in situ with chemoradiotherapy, and may go on to display a
complete response only after many months of follow up (Glynne-
Jones et al, 2012). Surgical salvage is possible, but undesirable if a
complete response is achieved. Predictive markers that allow real
time analysis (and may be prospectively compared with imaging
results) would be of significant clinical benefit. For those tumours
with residual/recurrent active disease, prompt surgical salvage is
associated with improved outcomes (Renehan et al, 2005); the
prognosis following R1 resection is poor.
Squamous Cell Carcinoma Antigen (SCCA) is a member of the
Serpin supergroup of proteins and raised plasma levels have been
reported across a number of squamous cancers including cervix,
head and neck. With respect to anal cancer, levels at baseline have
been reported to have prognostic value. Specifically 49% of 174
patients demonstrated raised plasma SCCA (Williams et al, 2013)
at presentation, correlating with reduced complete response to
treatment and reduced disease-free and OS. More recently there
has been interest in SCCA in follow up where one small study of 24
patients was not consistent with respect to baseline prognosis, but
during follow up, 2 patients demonstrated a rise of SCCA, one of
whom developed recurrence and metastatic disease (Henkenberens
et al, 2016).
More advanced techniques to use plasma-based assays that
inform on the biology of disease are now coming of age (O’Leary
and Turner, 2016) where changes in circulating tumour DNA may
be a more sensitive and specific way to predict outcome
to therapy through treatment (Garcia-Murillas et al, 2015).
Transformation Tumour biology Host response
Prognosis
HPV/p16+/TIL high
HPV/p16+/TIL mod
HPV/p16+/TIL low
HPV/p16–
p16 +ve
PIK3CA mutation
11q13
amplification
p53 mutation
CDKN2A mutation
HPV-dependent
pathway
HPV-independent
pathway
Squamous
epithelium
Co factors; smoking,
immunosuppresion,
inflammation
10–20%
80–90%
p16 –ve
Figure 1. A biological model of response to chemoradiotherapy in ASCC.
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Longitudinal analysis of cell free DNA is of particular interest, as
HPV DNA sequences, integrated into the genomes of anal cancer,
represent a unique signature of ongoing cellular activity given the
ubiquity of HPV in this cancer type (Baricevic et al, 2015). This
technique has recently been reported using HPV transcripts in
cervical cancer (Campitelli et al, 2012) and head and neck cancer
(Rutkowski et al, 2015) in a parallel setting (post chemo-
radiotherapy). Not all HPV-associated tumours harbour integrated
viral genomes and additionally some of the tumours at highest
risk of relapse will be truly HPV negative, so alternative cfDNA
targets will also be required for disease monitoring. Importantly,
prospective assessment of such cfDNA in anal cancer is required to
define the performance characteristics of these tests as compared
with and correlated with differing imaging modalities and follow-
up schedules.
Similarly there is evidence that microRNAs are involved in
HPV-induced transformation of cells in cervical and head and
neck cancers at least (Lajer et al, 2012) and potentially mediating
response to treatment. By their nature microRNAs are relatively
stable and again are being investigated in other HPV-associated
tumour types as longitudinal markers of disease state (Summerer
et al, 2015).
IMAGING-BASED PROGNOSTIC FACTORS, DETECTION
OF RELAPSE AND FUTURE POTENTIAL
A comprehensive review of imaging biomarkers for anal cancer is
beyond the scope of this review, but clearly approaches to refine
treatment plans and optimise response assessment will require
integration of both biological and imaging parameters. The role of
imaging in treatment stratification and assessment of response/
relapse has evolved in recent years reflecting the technological
advances that have enabled high resolution anatomical imaging to
be combined with functional imaging techniques, exemplified by
multi-parametric magnetic resonance imaging (MRI) (Jones
et al, 2015) and 18-F fluorodeoxyglucose positron emission
tomography (18F-FDG PET) either integrated with computed
tomography (CT) (Jones et al, 2015) or more recently with MRI
(Goh et al, 2016). Combining the metabolic information from
18F-FDG PET with the high spatial and contrast resolution of
anatomical MRI allows accurate delineation of the primary
tumour and locoregional nodes for staging and radiotherapy
planning, particularly with the incorporation of diffusion-
weighted MRI (Mandegaran et al, 2016) and also prognostic
information (Mohammadkhani et al, 2016).
Following therapy, early size-based MRI evaluation (within 8
weeks of completed therapy) has its limitations (Goh et al, 2010)
due to co-located radiotherapy changes; however, a tumour
regression grade (TRG) score may have promise in identifying
patients who would benefit from salvage surgery (Kochhar et al,
2016). Resolution of 18F-FDG PET activity is effective in detecting
complete responders although persistent low grade metabolic
activity may not necessarily reflect residual tumour activity
(Schwarz et al, 2008). More recently imaging radiomic approaches
have been investigated as potential imaging biomarkers in the
therapy response setting. The texture heterogeneity information
captured by these post-processing tools appear to augment current
morphological assessment. Greater MRI heterogeneity may be
apparent post-therapy in non-responders (Prezzi et al, 2016), and
in the future integrated radiomic approaches combining imaging,
clinical and pathological information may allow a more persona-
lised approach to anal cancer management. Again, however,
clinical utility will require sufficient levels of quality assurance and
reproducibility and validation in prospective studies (O’Connor
et al, 2016).
ONGOING TRIALS AND TRANSLATIONAL
OPPORTUNITIES
One key question in ASCC is whether the prognostic effect
seen through TILs can be manipulated via stimulating the host
immune response, either through immune checkpoint inhibition
or therapeutic vaccination. Immune checkpoint inhibitors
have demonstrated encouraging responses in metastatic ASCC
(Ott et al, 2015; Morris et al, 2016). There are a range of potential
therapeutic vaccine approaches currently in development (Khallouf
et al, 2014), and clinical trials of one such approach underway in
both metastatic and locoregional anal cancer (NCT01671488;
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil
(5-FU) and IMRT for Anal Cancer). An important component of
these studies in ASCC should be to ascertain whether either
strategy can elicit increases in the local/systemic immune response
where little is currently seen (i.e., improve outcomes in the
HPV ve or TIL low groups) or whether these novel approaches
work best in tumours that already elicit a response (i.e., might
facilitate reduced intensity treatment).
An alternative approach is to personalise radiotherapy doses by
our current understanding of risk, aiming to intensify treatment for
poor risk tumours, and test whether lower doses (and potentially
less toxicity) can safely be administered to those with a better
prognosis. Cancer Research UK has recently funded the PLATO
platform of clinical trials (ISRCTN88455282). The three trials,
ACT3, 4 and 5, are designed to personalise the use and dose of
radiotherapy across the locoregional disease spectrum (Sebag-
Montefiore et al, 2016). These studies provide an ideal platform for
the prospective analysis/validation of a number of the biomarkers
discussed here and potentially answer questions around whether
increased radiotherapy dose can make up for biologically
aggressive features and/or tumours with favourable biology can
be cured with less toxic regimens.
Finally, an improved understanding of the molecular biology of
anal cancer integrated with associated biomarkers and therapeutic
agents might yet allow ASCC patients to benefit from a targeted
approach. In the setting of relapsed or metastatic disease, the
consistent activation of PI3 kinase signalling through frequent
PIK3CA mutation (seen across the HPV-associated tumours)
supports the development of clinical trials in this setting.
Preclinical data supports this approach with mTOR inhibition
showing evidence of efficacy in anal cancer models (Sun et al,
2013). The clinical trial platforms currently being developed can
then be adapted to test these approaches as studies and data
progress.
A challenge to all these approaches will be in sourcing the
biological material to facilitate further understanding and develop
biomarker driven trials. A combined approach encouraging
additional biopsies (both at diagnosis, during treatment or at
relapse), increased use of plasma-based detection and ongoing
improvements in technology will be required to maximise output.
Achieving this within the context of clinical trials brings the
potential to then properly validate such biomarkers to optimise
future treatment.
CONCLUSIONS
SCCA is a tumour where the primary treatment modality is
chemoradiotherapy, with surgery as salvage. As such it provides a
model system for comprehensive translational science investigating
HPV-associated cellular transformation, staging and stratification
of treatment protocols and response assessment with outputs
relevant across the spectrum of HPV-associated tumours
(oropharynx, cervix, vulva) and beyond.
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Our current understanding of prognostic biomarkers offers
insights into how biological factors mediate disease progression
and response. Integrating this understanding into current and
future clinical trials should in the future allow the improved
stratification of treatment and facilitate novel therapeutic inter-
vention to improve outcomes for all patients with the disease.
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